Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post-Program Implementation:...

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• South Australia implemented a 4-component meningococcal B (4CMenB) vaccine program for adolescents in 2019.
• The study evaluates the long-term vaccine effectiveness (VE) and impact on gonococcal infections 4 years post-implementation.

Purpose of the Study:

• To assess the long-term effectiveness of the 4CMenB vaccine against gonococcal infection.
• To evaluate the vaccine's impact on reducing gonococcal infection rates and recurrence.

Main Methods:

• Utilized disease notification data from SA Health.
• Employed screening and case-control methods to estimate VE.
• Conducted time-to-event analyses for reinfections and negative binomial regression for vaccine impact (VI).

Main Results:

• Two-dose 4CMenB vaccine showed 44.3% VE against gonorrhea, decreasing to 26.2% after 4 years.
• VE was higher in females (48.7%) than males (38.0%).
• Vaccination was associated with a 36.5% reduction in gonococcal infection incidence and a lower risk of reinfection.

Conclusions:

• The 4CMenB vaccine offers moderate, albeit waning, effectiveness against gonococcal infections.
• The vaccine may play a role in reducing recurrent gonorrhea cases.
• Further evaluation of booster doses and optimal dosing intervals is warranted.